Sunshine Biopharma, Inc.
SBFM
$1.55
-$0.04-2.52%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 8.10% | -72.66% | -83.85% | 45.21% | 24.59% |
| Total Depreciation and Amortization | 52.11% | 54.25% | 73.66% | 45.85% | 22.77% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -- | -100.00% | 100.00% | -- | -- |
| Change in Net Operating Assets | 69.38% | 11.33% | -244.73% | -42.04% | -972.37% |
| Cash from Operations | 46.19% | -26.68% | -197.62% | -21.17% | -72.16% |
| Capital Expenditure | 88.08% | -126.83% | -5,285.42% | -114.18% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 72.19% | 34.18% | -315.44% | 122.03% | -316.36% |
| Cash from Investing | 73.68% | -97.44% | -3,160.32% | -108.94% | -357.07% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 41.89% | 367.17% | -1.37% | 11.73% | 6.03% |
| Issuance of Common Stock | -95.85% | 70,256.52% | -- | -100.00% | -- |
| Repurchase of Common Stock | -- | -- | 100.00% | -- | -519.51% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -93.74% | 6,834.43% | 3,033.96% | -100.70% | 1,102.81% |
| Foreign Exchange rate Adjustments | 97.47% | -245.84% | 302.49% | -287.54% | -16,196.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -236.78% | 1.32% | 179.11% | -1,461.47% | 145.10% |